Anbio Biotechnology is expanding its reach into the European healthcare sector with its premiere AF-100 C, a compact fluorescent immunoassay analyser designed to redefine point-of-care diagnostics. With a comprehensive range of over 70 assays, the AF-100 C aims to augment the capabilities of healthcare providers across the EU, thereby improving patient diagnosis and overall care.
Anbio Biotechnology (Anbio), a leader in the global in vitro diagnostics arena, is excited to present its broad “Point of Care” product lineup to the European Union. This launch is a pivotal step for Anbio, marking the beginning of new partnerships with EU distributors and medical organizations, and reinforcing the company’s commitment to bringing innovative diagnostic tools to the EU market.
Anbio is recognized for its innovation and quality, evolving beyond its initial focus on Covid test kits to become a comprehensive developer and manufacturer of a wide variety of diagnostic products. “Our mission is to revolutionize diagnostics by offering tailored and accessible solutions, including laboratory, wellness, at-home, and point-of-care diagnostics. We are committed to affordability and continuous innovation in life sciences that serve to advance human heath,” Michael Lau, CEO of Anbio, mentioned.
Next-Generation Analyzer Equips Providers with Over 70 Essential Diagnostics
The centerpiece of Anbio’s EU campaign is the AF-100 C analyzer, a sophisticated, single-channel, portable, rechargeable compact fluorescent Immunoassay (FIA) analyzer. This advanced device, together with over 70 CE-marked assays for a vast range of analytes such as inflammation markers, diabetes, cancer markers, hormones, enzymes, and infectious diseases, is anticipated to dramatically reshape the clinical diagnostics landscape within the EU.
“The Anbio AF-100 C is a game-changer for clinical diagnostics, supplying healthcare providers with a cost-effective, comprehensive, and reliable solution for rapid point-of-care testing,” Lau stated. The AF-100 C, despite its compact form, is capable of high throughput and is adaptable for use across a spectrum of clinical environments, from local clinics to major hospital emergency rooms. Its intuitive interface and durable battery, which allows for up to 8 hours of continuous testing, ensure that healthcare professionals can offer exceptional patient care with the highest efficiency and precision.
Rapid and Precise Diagnostics to Improve Healthcare Services
Anbio’s wide-ranging FIA lineup, capable of generating fast results within 3 to 15 minutes, signals a significant advancement in diagnostic technology. Featuring reagents that utilize RFID chip technology for superior accuracy and a two-year room temperature shelf life, Anbio is well-prepared to meet the immediate requirements of the European healthcare community.
As Anbio Biotechnology makes its mark on the EU market, it encourages distributors and healthcare professionals to discover its state-of-the-art diagnostic solutions. With a focus on enhancing patient care through affordable, accurate, and dependable diagnostics, Anbio is keen on establishing collaborations with healthcare practitioners across the European Union.
